Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pien Tze Huang after curative hepatectomy for prevention of hepatocellular carcinoma recurrence
ChiCTR2200064498Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Oct 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Pien Tze Huang in hepatocellular carcinoma (HCC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: 2-year recurrence-free survival rate assessed by blinded independent central review. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
Pien Tze Huang
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200064498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064498.